Global Tuberculosis Control 2010 - Florida Department of Health

More documents

Recommendations

Info

2819 22 HBCs Afghanistan Bangladesh Brazil Cambodia 63 21 45 64 38 2536 59 36 2248 5 5 25 25 14 931 0 9 17 3 394 China DR Congo Ethiopia India Indonesia 64 39 147 94 64 39 239 31 112 112 71 208 19 45 50 8 6 45 12 US$ millions (constant 2010 US$) b 46 5 43 Kenya Mozambique Myanmar Nigeria Pakistan 32 21 63 88 31 38 14 37 8 28 12 8 3 1 7 5 Philippines Russian Federation South Africa Thailand Uganda 43 1286 43 1258 413 52 23 1227 54 35 20 14 704 258 273 273 47 2 4 UR Tanzania Viet Nam Zimbabwe 2002 2005 2008 2011 2002 2005 2008 2011 34 20 21 30 21 6 2002 2005 2008 2011 13 13 9 2002 2005 2008 2011 18 10 2 2002 2005 2008 2011 NTP budget Available funding
Russian Federation Thailand Brazil South Africa China Philippines Viet Nam India Indonesia Kenya Pakistan Mozambique Nigeria Ethiopia Afghanistan UR Tanzania Cambodia Uganda Myanmar Zimbabwe Bangladesh DR Congo Internal sources Government, NTP budget (excluding loans) Government, general health-care services (excluding loans) Loans External sources Grants (excluding Global Fund) Global Fund 0 10 20 30 40 50 60 70 80 90 100 % of total available funding 40% of available funding in India to more than 90% of available funding in the Democratic Republic of the Congo (). There is also considerable variation in the estimated cost per patient treated according to the DOTS strategy ( ). This ranges from under US$ 100 (in Bangladesh, India, Myanmar, Pakistan and Zimbabwe) to around US$ 750 in Thailand, US$ 1000–1500 in Brazil and South Africa and more than US$ 7 500 in the Russian Federation. In most HBCs, the cost per patient treated under DOTS is around US$ 150–400. As shown in , variation in the cost per patient treated is clearly related to income levels (for example, Brazil and South Africa are upper-middle income countries, where prices for inputs such as NTP staff and hospital care are higher than in low-income countries). The major reason why the Russian Federation is an outlier is the model of care used: high costs are associated with a policy of lengthy hospitalization of TB patients within an extensive network of TB hospitals and sanatoria. A further explanation for variation in costs appears to be the scale at which treatment is provided. The countries with relatively low costs for their income level (for example, Bangladesh, China, India, Indonesia and the Philippines) are also the countries where the total numbers of patients treated are highest (as shown by the size of the circles in ). A similar pattern exists for the cost per patient successfully treated, which combines information about both costs and effectiveness ( ). Besides the 22 HBCs, 81 other countries have reported financial data to WHO since 2006 that allow assessment of trends in funding for TB control. Combined, these 103 countries account for 96% of the world’s notified cases of TB. Funding for TB control has grown from US$ 3.9 billion in 2006 to a projected US$ 4.7 billion in 2011 (, ). As in HBCs, the largest share of funding is for DOTS implementation; an increasing amount is for MDR-TB. National governments account for 86% of the funding expected in 2011, followed by the Global Fund (US$ 513 million, or 11% of total funding) and then by grants from donors besides the Global Fund (US$ 101 million, or 2%). Loans from development banks account for the remaining 1% of total funding. The funding gaps reported by these 103 countries amount to US$ 0.6 billion in 2010 and US$ 0.3 billion in 2011 ( ). A comparison of the funding available in the countries that reported financial data with the funding requirements set out in the Global Plan is provided, by region and for the period 2011–2015, in . 1 Overall, funding falls short of the requirements of the Global Plan. The gap is approximately US$ 1 billion in 2011. Given the scale-up of interventions set out in the plan, this could increase to US$ 3 billion by 2015 without intensified efforts to mobilize more resources. 1 This analysis is for the 22 HBCs and a subset of 85 other countries that are among the 149 countries considered in the Global Plan. The total funding available in the group of 107 countries for which data were available was adjusted upwards according to the fraction of cases for which they accounted, to allow direct comparison with the group of 149 countries considered in the Global Plan. The Global Plan excludes high-income countries.
Page 1: Global Tuberculosis Control 2010
Page 4 and 5: Global Tuberculosis Control 2010
Page 6 and 7: his report on global tuberculosis c
Page 8: Francis Morey, Mercianna Moxey, Mir
Page 11 and 12: he World Health Organization (WHO)
Page 13 and 14: provides details about the methods
Page 15 and 16: Estimated new TB cases (all forms)
Page 17 and 18: lobal targets for reducing the burd
Page 19 and 20: his section examines the latest dat
Page 21 and 22: Myanmar (45%), Kenya (46%) and Ethi
Page 23 and 24: indicating that case detection is i
Page 25 and 26: (); and reimbursement for TB care d
Page 27 and 28: Number of TB patients (thousands) 5
Page 29 and 30: Number of people screened (thousand
Page 31 and 32: Belarus Republic of Moldova Georgia
Page 33 and 34: Belarus Republic of Moldova Georgia
Page 35: US$ billions (constant 2010 US$) a
Page 39 and 40: US$ billions (constant 2010 US$) b
Page 41 and 42: ogress made towards achieving the i
Page 43 and 44: Africa The Americas Eastern Mediter
Page 45 and 46: Rate per 100 000 population 80 60 4
Page 47 and 48: stimates of TB incidence, prevalenc
Page 49 and 50: analysing surveillance and programm
Page 51 and 52: his section summarizes the main con
Page 54: elated interventions such as ART, m
Page 57 and 58: the Western Pacific Region). For so
Page 59 and 60: First, the variance for the distrib
Page 61 and 62: has been estimated by UNAIDS as an
Page 63 and 64: 35-44 years, 45-54 years, 55-64 yea
Page 65 and 66: parameter (except for notifications
Page 68 and 69: parameter (except for notifications
Page 70 and 71: Estimated values are shown as best
Page 86 and 87:
Estimated values are shown as best
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 216:
85 80 75 70 65 60 55 50 45 40
show all

Global Tuberculosis Control 2010 - Florida Department of Health

Create successful ePaper yourself

Delete template?

Save as template?